Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis

Meng-Ya Shan,Ying Dai,Xiao-Dan Ren,Jing Zheng,Ke-Bin Zhang,Bin Chen,Jun Yan,Zi-Hui Xu

Journal of Integrative Medicine（2021）

引用 16|浏览4

暂无评分

摘要

BBR can mitigate FFA-induced steatosis in HepG2 cells by activating SIRT1-FoxO1-SREBP2 signal pathway. BBR may emerge as a potential drug candidate for treating nonalcoholic hepatic steatosis.

查看译文

关键词

Berberine,Nonalcoholic fatty liver disease,Lipid metabolism,SIRT1-FoxO1-SREBP2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要